» Articles » PMID: 37656757

A Qualitative Study of Imaginary Pills and Open-label Placebos in Test Anxiety

Overview
Journal PLoS One
Date 2023 Sep 1
PMID 37656757
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The efficacy of open-label placebos (OLPs) has been increasingly demonstrated and their use holds promise for applications compatible with basic ethical principles. Taking this concept one step further an imaginary pill (IP) intervention without the use of a physical pill was developed and tested in a randomized controlled trial (RCT). To explore participants' experiences and views, we conducted the first qualitative study in the field of IPs.

Methods: A reflexive thematic analysis (RTA) of semi-structured interviews with test anxious students (N = 20) was nested in an RCT investigating an IP and OLP intervention. In addition, open-ended questions from the RCT were evaluated (N = 114) to corroborate the RTA and pill characteristics were included to more accurately capture the IP experience.

Results: Four key themes were identified: (1) attitude towards the intervention, (2) applicability of the intervention, (3) experience of effects, and (4) characteristics of the imagination. The IP intervention was well-accepted, easily applicable, and various effects, pill characteristics and appearances were described. While many participants did not desire a physical pill, either due to the absence of the imagination component or aversion to pills, the approach was considered to be cognitively and time demanding, which in turn, however, encouraged the establishment of a therapeutic ritual that protected against the increase in test anxiety during the preparation phase. OLP findings were comparable, and especially the importance of a treatment rationale was stressed in both groups, counteracting an initial ambivalent attitude. The RTA findings were supported by the open-ended questions of the RCT.

Conclusion: IPs appear to be a well-accepted and easily applicable intervention producing a variety of beneficial effects. Thus, the IP approach might serve as an imaginary based alternative to OLPs warranting further investigations on its application to harness placebo effects without a physical pill.

References
1.
Druart L, Vauthrin O, Pinsault N, Locher C, Blease C . 'It's not my greengrocer, it's someone from the medical profession': A qualitative study regarding acceptability of deceptive and open-label placebo prescribing in France. Br J Health Psychol. 2022; 28(2):273-290. DOI: 10.1111/bjhp.12624. View

2.
Sandelowski M . Whatever happened to qualitative description?. Res Nurs Health. 2000; 23(4):334-40. DOI: 10.1002/1098-240x(200008)23:4<334::aid-nur9>3.0.co;2-g. View

3.
Locher C, Frey Nascimento A, Kirsch I, Kossowsky J, Meyer A, Gaab J . Is the rationale more important than deception? A randomized controlled trial of open-label placebo analgesia. Pain. 2017; 158(12):2320-2328. DOI: 10.1097/j.pain.0000000000001012. View

4.
Enck P, Bingel U, Schedlowski M, Rief W . The placebo response in medicine: minimize, maximize or personalize?. Nat Rev Drug Discov. 2013; 12(3):191-204. DOI: 10.1038/nrd3923. View

5.
von Wernsdorff M, Loef M, Tuschen-Caffier B, Schmidt S . Effects of open-label placebos in clinical trials: a systematic review and meta-analysis. Sci Rep. 2021; 11(1):3855. PMC: 7887232. DOI: 10.1038/s41598-021-83148-6. View